Sanofi's Nuvaxovid Vaccine Shows Lower Reactogenicity than Moderna's
Sanofi (SNY) said its protein-based non-mRNA COVID-19 vaccine Nuvaxovid demonstrated statistically significant lower systemic reactogenicity compared to mNEXSPIKE, Moderna's (MRNA) latest mRNA COVID-19 vaccine, across all pre-specified endpoints in the COMPARE study. The randomized, double-blind study enrolled 1,000 adults in the U.S. The study met its primary endpoint - the probability of experiencing at least one systemic reaction within seven days of vaccination - with statistical significance, with 91.6% of mNEXSPIKE recipients affected compared to 83.6% of Nuvaxovid recipients. The study also showed that 61.3% of mNEXSPIKE recipients experienced moderate-to-severe systemic symptoms versus 43.1% of Nuvaxovid recipients, and 58.7% of mNEXSPIKE recipients experienced moderate-to-severe local symptoms versus 38.7% of Nuvaxovid recipients. "In the COMPARE study, when side effects did occur with Nuvaxovid, they were less severe and shorter in duration compared to mNEXSPIKE. Severe systemic symptoms (body-wide reactions such as fatigue, headache, or fever) that prevent people from carrying out their normal daily activities were more than 50% less frequent with Nuvaxovid, affecting fewer than one in ten Nuvaxovid recipients compared to one in five mNEXSPIKE recipients, an analysis of the data showed," Sanofi said in a statement.
